Floatz Rating
B61/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06551142CT.gov A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) | — | Recruiting | — | — | — |
NCT04900818CT.gov Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04873440CT.gov An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma | — | Unknown | — | — | — |
NCT04696848CT.gov The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors | — | Terminated | — | — | — |
NCT04613492CT.gov A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors | — | Terminated | — | — | — |
NCT03991832CT.gov Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT04078152CT.gov Durvalumab Long-Term Safety and Efficacy Study | — | Completed | — | — | — |
NCT03911557CT.gov Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | — | Completed | — | — | — |
NCT03946800CT.gov A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03693612CT.gov GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors | — | Completed | — | — | — |
Show 10 more trialsShow fewer
NCT03238027CT.gov A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | — | Completed | — | — | — |
NCT02643303CT.gov A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | — | Completed | — | — | — |
NCT02737072CT.gov A Study of LY2510924 and Durvalumab in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT02754856CT.gov Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery | — | Completed | — | — | — |
NCT02793466CT.gov Durvalumab in Pediatric and Adolescent Patients | — | Completed | — | — | — |
NCT02718911CT.gov A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT02556463CT.gov A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors | — | Terminated | — | — | — |
NCT02503774CT.gov MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors. | — | Completed | — | — | — |
NCT02318277CT.gov A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | — | Completed | — | — | — |
NCT02118337CT.gov A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | GlaxoSmithKline | Approved | B · 61 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →